ar personal use $\mathbf{Q2}$ <u>I</u> **QUARTERLY UPDATE**



ASX RELEASE DATE: 28 AUGUST 2024





MARKET & FUND SERIES

In the first half of 2024, the US private equity (**PE**) market exhibited positive trends amidst ongoing concerns about a growing backlog of assets. The small to mid-size PE segment, particularly relevant to the CD Fund Series, demonstrated a blend of cautious optimism and strategic recalibration.

Private equity managers, known for their long-term investment perspective, strategically time their asset sales. These exits are critical to the PE capital formation cycle, influencing distributions to limited partners (**LPs**) and impacting future fundraising, fund deployment, and overall performance.

As noted in previous reports, the persistent gap between buyer and seller valuations has slowed exit activity, with the exit-to-investment ratio dropping to a record low of 0.36x in Q1 2024¹⁰. While exit volumes remain below the peak levels of 2020 and 2021, Q2 2024 has seen a positive shift, marked by an increase in partial sales and minority stake rollovers.

Despite the prevailing market challenges, the CD Fund Series has shown resilience. The recent market uptick in exit activity and improvements in valuation multiples suggest a cautiously optimistic outlook. Several portfolio companies are currently in the pipeline for sale, with some having already signed Letters of Intent. These sales remain the key driver of our distributions to Unitholders, with A\$75 million distributed to Fund Series Unitholders since July 2023.

We look forward to sharing more details at our upcoming Investor Webinar on Friday, September 6th (details can be found <u>here</u>). As always, Unitholders may reach out to the Investor Relations team via email at <u>cdfunds@k2am</u>. <u>com.au</u> or by phone at (03) 9691 6110.

FUND 3: QUARTERLY UPDATE

30 JUNE 2024: KEY STATISTICS					
NTA per unit	Gross assets (million)	Quarterly NTA Return			
\$1.80	A\$134.5	-1.1%			

Q2 2024 Net Tangible Asset (**NTA**) movement is largely attributable to positive portfolio revaluations, which were mostly offset by the Australian dollar strengthening by 2.3% between 31 March 2024 and 30 June 2024.

The period ended **30 June 2024 (Q2 2024)** saw two additional portfolio company realisations for CD3, taking the year-to-date total to four realisations. We explore these in greater detail on *Page 4* of this report.

Additionally, though the quarter was relatively quiet, the LP made payment of **US\$0.2m** in capital calls as well as receiving **US\$0.6m** in distributions. In addition to funding management fees and partnership expenses, these capital calls were to fund continued growth and liquidity for existing portfolio companies: Aqualis, Starwest Botanicals and Raney's. We explore these companies in further detail on *Page 5*.

NET TANGIBLE ASSET VALUE

We acknowledge that the Fund's underlying investments and their valuations are somewhat opaque due to our commitment to confidentiality with the underlying Managers. However, we want to emphasise that the Fund's NTA is intended to be the most accurate reflection of the realisable value of individual investments in the current market.

The NTA serves as a reliable measure of the Fund's value, employing various valuation techniques such as discounted cash flows, comparable companies, and EBITDA multiples¹¹. These valuations are updated at least quarterly and are audited by independent parties throughout the year.

Private equity managers typically adopt a conservative approach to minimise significant valuation fluctuations, with an aim to realise investments at or above the current book value. This conservative approach is evidenced by the Fund's 53 realisations (including four realisations of zero value) from 2020 to date, recording an **average uplift of +46%** to the pre-sale valuation¹², highlighting the inherent value within the portfolio.

Ultimately, K2 and the Manager maintain confidence in the robust valuation methods employed and the underlying fund managers desire to underpromise and over-deliver wherever possible. We demonstrate this graphically on *Page 3*.




QUARTERLY INVESTMENT UPDATE FUND 3 (ASX: CD3)

PORTFOLIO COMPOSITION^{1, 5, 7, 8}

Inception Date	July 2016
CD3 Original Unit Price	\$1.60 per unit
CD3 Distributions Paid Since Inception	\$1.839 per unit
CD3 30 June 2024 NTA (post-tax)	\$1.80 per unit
CD3 Interest in LP3	71.22%
Total Underlying Funds (since inception)	13
Total Underlying Portfolio Companies (since inception)	144
Total Portfolio Company Realisations	63
Remaining Portfolio Companies	81
Median Gross MOIC on Realisations	3.1x
Average Hold Period of Remaining Investments	5.2 years
Fund Cash Balance (inclusive of distributions not yet paid)	A\$12.8m
Fund's Interest in LP Cash Balance (inclusive of distributions not yet paid)	US\$5.8m
Fund's Interest in Underlying Funds	US\$58.0m
Fund's Interest in US Select Direct II (USD2)	US\$24.8m

FUND + LP OUTSTANDING CAPITAL COMMITMENTS (\$USD millions)¹

Fund's Remaining Commitment to LP3 LP3's Remaining Commitment to Underlying Funds⁹



The LP's remaining capital commitments are subject to change as allowed under the individual Limited Partnership Agreement (LPA). Though the remaining commitment will change with each capital call or distribution, it is the Manager's expectation that the underlying Funds will not call this full amount, and that any capital calls should be funded by distributions in the future.

LP3: AVERAGE PORTFOLIO COMPANY UPLIFT AT SALE^{1, 5, 12}

70% 15 Realisations 59% Uplift 60% 20 Realisations 54% Uplift 50% 40% 7 Realisations 33% Uplift 30% 11 Realisations 23% Uplift 20% 10% 0% 2021 FY 2022 FY 2023 FY 2024 FY Email: cdfunds@k2am.com.au | Phone: +61 3 9691 6110 | Web: www.cdfunds.com.au

Average Uplift to Carrying Value at Sale (from 2020FY to date)

US\$3.6m

US\$13.9m

LP3 UNDERLYING PORTFOLIO^{1,5,7,8}

		TOTAL COMPANIES	TOTAL REALISATIONS	MEDIAN MULTIPLE ON INVESTED CAPITAL (MOIC)	REMAINING COMPANIES	AVERAGE HOLD PERIOD ON REMAINING COMPANIES	REMAINING VALUE (\$USD millions)
	Fund 1	9	6	4.1x	3	6.3 years	\$4.49
	Fund 2	7	3	2.5x	4	6.1 years	\$3.02
	Fund 3	11	8	3.3x	3	6.7 years	\$7.82
	Fund 4	12	5	2.9x	7	5.6 years	\$8.43
$(\Box$	Fund 5	12	5	4.6x	7	5.4 years	\$8.09
	Fund 6	9	5	7.8x	4	4.2 years	\$4.75
$(\Box$	Fund 7	10	4	3.9x	6	4.2 years	\$4.47
9	Fund 8	7	7	2.2x	0	-	\$5.14
	Fund 9	8	0	-	8	4.9 years	\$12.38
\square	Fund 10	12	5	3.8x	7	6.3 years	\$4.74
Y	Fund 11	7	2	4.3x	5	4.5 years	\$12.36
61	Fund 12	15	9	1.2x	6	5.0 years	\$5.25
\square	Fund 13	25	4	2.7x	21	3.9 years	\$34.83
	Total	144	63	3.1 ×	81	4.9 years	\$115.77

Fund 8 has had all underlying portfolio companies substantially exited, with two realisations having approximately 1/3 of the exit proceeds retained as rollover equity. Table excludes direct investment in Smartsheet (US\$0.5m). Remaining value is at the LP level.

Q2 2024 PORTFOLIO REALISATIONS





<u>Govenda</u>, a board portal and corporate governance software platform known for artificial intelligence (AI) applications, was sold during the quarter to OnBoard, a leading provider of digital board governance solutions and portfolio company of JMI Equity.

During the hold period of 3.5 years, GSP1 worked with Govenda to build out their product line and assert themselves as a key player in the market. They were able to launch innovative new products and features as well as grow their customer base, resulting in year-over-year growth in annual recurring revenue and the addition of new customers in a range of industries, including financial institutions, healthcare, higher education, and trade associations. The partnership with GSP1 culminated in a successful exit for both parties.

Shorecal Limited, the largest Domino's franchise, operates 34 of the 99 stores in the Republic of Ireland and Northern Ireland. USDII first invested in the company in 2018, where the company operated 26 stores. The original investment premise was to continue to increase operations with a plan for up to 10-stores over the first five years as well as to increase profitability of the existing stores.

In March 2024, the company entered into a binding sale agreement with Domino's Pizza Group (DPG) for a total consideration of €72m (which was closed in April 2024). Shorecal's reported book value as of December 2022 was €54.3m.

CD3 PERFORMANCE SUMMARY^{1, 2, 3, 4}

	1 MONTH	6 MONTHS	12 MONTHS	3 YEARS	5 YEARS	SINCE INCEPTION	IRR
NTA RETURN	0.0%	4.4%	3.7%	17.7% p.a.	19.1% p.a.	13.6% p.a.	13.3%

HISTORICAL PERFORMANCE IS NOT A GUARANTEE OF THE FUTURE PERFORMANCE OF THE FUNDS.

CD3: PORTFOLIO COMPANY UPDATE



Status current portfolio company

Initial Investment Date 2018

<u>Underlying Fund</u> DFW Capital Partners V, LP.



<u>Status</u> current portfolio company

Initial Investment Date 2022

Underlying Fund Incline Equity Partners IV, LP. <u>Aqualis</u> specialises in water treatment and purification solutions. Their focus is on providing advanced technologies and services for improving water quality. This includes solutions for various applications such as industrial processes, residential needs, and commercial use. They offer products and services related to filtration, disinfection, and overall water management to ensure clean and safe water.

During the hold period, the company has completed eight add-on acquisitions, which has enabled the company to broaden the service capabilities and attract additional clients. Moving forward, the company will continue to integrate their recent acquisitions, refine the sales model and build out organic sales.

Recent company updates here.

<u>Raney's Truck Parts</u> (Raney's) specialises in providing a wide range of aftermarket truck parts and accessories, offering products for both heavyduty and light-duty trucks, including items like chrome accessories, lighting, bumpers, and other custom parts. Their focus is on enhancing the functionality and appearance of trucks, catering to both professional drivers and truck enthusiasts. The company provides parts for various truck makes and models, ensuring a broad selection to meet diverse customer needs.

During the hold period, the company has completed five add-on acquisitions (including one in Q1 2024), expanded the c-suite, added new product offerings and enhanced the digital marketing strategy. Moving forward, the company will further enhance their offerings and extend their reach while upholding Raney's core values and dedication to customer service.

Recent company updates: Raney's: Revolutionising the Truck Parts Industry (<u>here</u>), Incline Equity Partner's investment thesis (<u>here</u>).



<u>Status</u> current portfolio company

Initial Investment Date 2021

<u>Underlying Fund</u> Incline Équity Partners IV, LP. <u>Starwest Botanicals</u> specialises in providing high-quality herbs, spices, and botanical products. They offer a wide range of items including dried herbs, essential oils, teas, and natural personal care products. The company focuses on sourcing and supplying organic and sustainably harvested ingredients for both personal use and for businesses in the herbal and natural products industries. Their product offerings cater to customers seeking natural and holistic health solutions.

During the hold period, Incline has focussed on developing the management team, improving operational performance and driving organic growth.

Recent company updates: CEO appointed for Starwest Botanicals (<u>here</u>), Incline Equity Partner's investment thesis (<u>here</u>).

GLOSSARY AND NOTES

Source: E&P Investments Limited (for data before 24 June 2023) and K2 Asset Management Ltd (for data after 24 June 2023).

All figures are in AUD unless otherwise noted. Figures throughout the document may not sum due to rounding. AUD:UDD 30 June 2024 spot rate of 0.6670 used. The Unit price of CD3 was \$1.38 as at 28 June 2024, the last trading day of the quarter.

1. Data is unaudited and is as at 30 June 2024.

3.

10

11.

NTA and total returns are inclusive of distributions and are based on post tax NTA, net of fees and costs.

Inception dates were August 2012 (CD1), April 2013 (CD2), July 2016 (CD3) and April 2018 (CD4).

CD1, CD2, CD3 and CD4 original Unitholder investment was \$1.60 per

MOIC returns are as at 30 June 2024 and represent all underlying portfolio company sales since inception. MOIC returns are net of all underlying fees and expenses of the individual fund managers, but before fees and expenses of the LP and the Australian Unit Trust. MOIC returns are based on US dollar denominated investments and include US Select Direct II (USD2).

Includes US Select Direct II (USD2).

Age of portfolio companies refers to the average duration of time that the LP has been invested in the remaining underlying portfolio companies.

LP investments values are based on 31 March 2024 valuations provided by the underlying GP's, adjusted for capital calls, distributions and foreign exchange movements over the period.

The Manager has confirmed that USD2's remaining callable capital has been excluded from this figure, as the Fund is well capitalised and any future expenses are anticipated to be covered by distributions.

Abbott Year End 2023 Private Equity Market Overview (here).

For further insights into the nuances of private equity valuations, Russell Investments has published a comprehensive analysis that you can read

The uplift on exit compares the value received upon realisation against the investment's carrying value at the latest valuation which is unaffected by pricing effects arising from the sale of the asset (typically 6 to 12-months before a sale is agreed to). Data for realisations prior to 2020 was not available to the RE at the time of release.

DEFINED TERMS

Portfolio Company:

MOIC:

IRR:

TVPI

VINTAGE:

A company that is an investment of the LP. Multiple on Invested Capital. MOIC is calculated by dividing the fund's cumulative distributions and residual value by the paid-in capital. Internal Rate of Return. Performance of the fund(s) by taking into account the size and timing of its cash flows (capital calls and distributions) and the Fund's net asset value at the time of the calculation. Total Value to Paid-in Capital. Mergers & Acquistions. Transactions in which the ownership of companies or their operating units – including all associated assets and liabilities – is transferred to another entity. The year in which a private equity fund makes its first investment in the portfolio company.

INVESTMENT OBJECTIVES

The CD Private Equity Fund Series, including CD Private Equity Fund I (ASX: CD1), CD Private Equity Fund II (ASX: CD2), CD Private Equity Fund III (ASX: CD3), and CD Private Equity Fund IV (CD4) (together, Funds or Fund Series), is a series of private equity funds focused on US small-cap private equity funds to the function of the series of private equity funds. and direct company investments. The Fund Series investments are selected by a joint venture between the private investment arm of the Cordish Companies of Baltimore, Maryland, and E&P Funds with underlying investments managed by experienced private equity fund managers.

The General Partner and Investment Manager will seek to meet each Fund's aim of providing Unitholders with exposure to a portfolio of investments in small and mid-market private investment funds and privately held companies predominantly focused in the US; and capital growth over the medium to long term.

CORDISH EQUITY PARTNERS TEAM



Jonathan Cordish President **Cordish Equity Partners**



Jonathan Sinex Managing Director Cordish Equity Partners

RESPONSIBLE ENTITY



K2 Asset Management Ltd (K2) is the Responsible Entity of the Funds. K2 is a listed Australian diversified financial services firm with three core pillars:

- **Funds Management:**
- Responsible Entity (RE) and Trustee Service; and
- **Exchange Traded Funds (ETFs).**

Established in 1999, K2 is the main operating subsidiary of K2 Asset Management Holdings Ltd which is listed on the Australian Securities Exchange (ASX Code: KAM).

HISTORICAL PERFORMANCE IS NOT A GUARANTEE OF THE FUTURE PERFORMANCE OF THE FUNDS.

DISCLOSURES

This Quarterly Update (Update) has been prepared by K2 Asset Management Ltd (K2) as Responsible Entity (ACN 085 445 094, AFSL 244 393) of the CD Private Equity Fund Series (Funds or Fund Series) which includes CD Private Equity Fund I (ARSN 158 625 284) (CD1), CD Private Equity Fund II (ARSN 162 057 089) (CD2), CD Private Equity Fund III (ARSN 612 132 813) (CD3), and CD Private Equity Fund IV (ARSN 624 474 531) (CD4). K2 and the Manager have taken reasonable care to ensure that the information contained in this document is accurate at the date of publication. However, no warranty or guarantee (express or implied) is given by either party as to the accuracy of the information in this document, and to the extent permitted by applicable law, K2 and the Manager specifically disclaim any liability for errors, inaccuracies or omissions in this document and for any loss or damage resulting from its use.

The general partner of each of the Limited Partnerships (LPs) in the series has engaged either E&P Funds Management Pty Limited (ACN 159 902 708)(LPI)("E&PFM") or the Investment Manager (LPs II,III,IV) to act as investment manager and/ or investment advisor for each respective underlying LP. An investment in any of the Funds is subject to various risks, many of which are beyond the control of the Investment Manager and the Funds. The past performance of the Funds is not a guarantee of the future performance of the Funds. This Update may contain statements, opinions, projections, forecasts and other material (forward looking statements), based on various assumptions. Those assumptions may or may not prove to be correct. The Responsible Entity and its advisers (including all of their respective directors, consultants and/or employees, related bodies corporate and the directors, shareholders, managers, employees or agents of them) (Parties) do not make any representation as to the accuracy or likelihood of fulfilment of the forward-looking statements or any of the assumptions upon which they are based. Actual results, performance or achievements may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward-looking statements and the Parties assume no obligation to update that information. This Update may contain general advice. Any general advice provided has been prepared without taking into account your objectives, financial situation or needs. Before acting on the advice, you should consider the appropriateness of the advice with regard to your objectives, financial situation and needs, and consider obtaining advice from a financial advisor. You should obtain a copy of the relevant PDS or offer document before making any decisions to purchase a product. All performance figures, unit prices and distributions are in Australian Dollars, unless otherwise stated. Like all investments, an investment in any of the Funds carries risks which may result in the loss of income or principal invested. In addition to the general risks of investing, specific risks associated with investing in the Funds include, but are not limited to, private investments risk, illiquidity risk and foreign exchange risk.

For further information about the risks of investing in any of the Funds, please see the relevant Product Disclosure Statements available on the website:

